Kane Biotech Inc.

Kane Biotech Inc.

October 18, 2005 09:04 ET

Kane Biotech Selects KBI-5898 as its Lead Product for Coating Urinary Catheters

WINNIPEG, MANITOBA--(CCNMatthews - Oct. 18, 2005) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms, announces today that it has selected KBI-5898 as its lead product for applications related to combating medical device related infections. The product was chosen from a number of promising candidates, and is targeted for commercial development, with its first application being a urinary catheter coating.

"The selection of KBI-5898 for commercial development is an important milestone for the Company", stated Mr. Gord Froehlich, Vice President, Business Development of Kane Biotech Inc. "The results of internal studies with the product to date have been very impressive and encouraging."

KBI-5898 is a novel coating composition that has shown broad spectrum antimicrobial effects in laboratory (in vitro) tests and has demonstrated efficacy against both gram positive and gram negative bacteria. The selection of KBI-5898 as the Company's lead product was based on in vitro studies showing that the composition is particularly effective against catheter associated bacteria, such as Escherichia coli, Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa and additional uropathogens such as Candida albicans. It is widely recognized that biofilms formed by these pathogens is a primary cause of catheter associated urinary tract infections (CAUTIs). CAUTIs are estimated to cost the United States healthcare system over US$1 billion a year.

"The development goal for KBI-5898 is to move this product forward quickly, starting with external validation of the safety and efficacy of the product," continued Mr. Froehlich. "This will give us a solid foundation for the achievement of regulatory and commercial development milestones."

As Kane Biotech advances KBI-5898, it continues to evaluate promising peptides acting on its novel CSP target for the development of an anti-dental cavity product. The Company's CSP technology has shown the ability to inhibit the formation of biofilms in Streptococcus mutans, the predominant organism in the formation of dental cavities.

The Center for Disease Control in Atlanta has reported that one in ten patients in the United States will acquire an infection after admission to a hospital. The result is prolonged hospital stays, an additional US$5 billion in annual health costs and, most tragically, numerous deaths each year. Catheter associated urinary tract infections account for 40% of all hospital-acquired infections.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, other medical device related infections and tooth decay.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information